Vericel Corporation

XNASHealth care

Last traded price · USD

$45.48

+10.68%Market closed

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 03:25 IST · A quote does not mean the product is available to trade on your account.

Day's open: $42.07
Previous close: $41.09
Volume: 1.8M
Day's high: $45.98
Day's low: $42.07

In brief

Vericel Corporation is a health care company listed on Nasdaq, valued at about $2.33B.
Its shares closed at $45.48 on 4 Nov 2026, up 25.5% over the past year.
From India you can buy VCEL in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Vericel Corporation (VCEL) shares from India?

Yes. Indian residents can invest in the US stock market under the Reserve Bank of India's Liberalised Remittance Scheme (LRS), which lets a resident individual remit up to USD 250,000 per financial year, across all permitted purposes combined. US-listed stocks and ETFs are a permitted investment under the LRS. You are solely responsible for ensuring your remittances comply with the LRS annual limit, the applicable Tax Collected at Source (TCS) rules, and all reporting requirements, including Schedule FA in your income-tax return.

Do I need the price of a whole VCEL share to invest?

Yes. You can buy fractional shares, which lets you invest a fixed rupee/dollar amount even in high-priced stocks. For example, if one share trades at USD 1,000 and you invest USD 100, you receive 0.1 of a share.

How much can I invest in US stocks in a year?

Under the LRS, an Indian resident can remit up to USD 250,000 per financial year (April to March) across all permitted purposes combined, from their own funds. This is a per-individual limit set by the RBI.

Can I trade VCEL options or futures?

No. Under RBI / FEMA rules, the LRS does not permit margin trading or speculative instruments such as futures, options, or other derivatives. Your US account is a cash account, not a derivatives and margin account.

Insights

Quotes run fifteen minutes behind.

Rose 10.7% on 4 Nov 2026
The 4 Nov 2026 gain of 10.7% was 5.2× its average daily move of 2.0% over the past year, and its largest one-day gain since 9 Apr 2025.
Daily closes, split-adjusted · as of 4 Nov 2026
9.5 days to cover short interest
5.2M shares were sold short at the 15 Oct 2026 settlement, 10.2% of the 51.2M shares outstanding; covering them would take 9.5 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Volume 3.3× its 30-session average on 4 Nov 2026
4 Nov 2026 volume of 1.8M shares was 3.3× the average of the 30 sessions before it (548.1K), as the price rose 10.7%. SPY traded 1.5× its own average that session.
Daily volume against a 30-session baseline · as of 4 Nov 2026
Ahead of SPY, behind its sector fund XLV over 1 year
1 month: +13.6% (SPY −1.6%, XLV +13.5%). 3 months: +0.3% (SPY −0.4%, XLV +15.5%). 1 year: +25.5% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: VCEL, SPY and XLV · as of 4 Nov 2026
Above its 50- and 200-day averages
The 4 Nov 2026 close of $45.48 was 12.1% above its 50-day average ($40.56) and 17.4% above its 200-day average ($38.72). It has closed above the 200-day for 39 sessions, since 11 Sep 2026. The 50-day average crossed above the 200-day on 23 Jun 2026, 94 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month+13.6%

6 months+23.7%

1 year+25.5%

5 years−6.5%

Newswire

About

Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.

Website

Notable moves

November 10, 2022
+26.97%
November 9, 2022
−23.43%
February 24, 2022
+20.82%

Vericel Corporation

XNASHealth care

Last traded price · USD

$45.48

+10.68%Market closed

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 03:25 IST · A quote does not mean the product is available to trade on your account.

Day's open: $42.07
Previous close: $41.09
Volume: 1.8M
Day's high: $45.98
Day's low: $42.07

In brief

Vericel Corporation is a health care company listed on Nasdaq, valued at about $2.33B.
Its shares closed at $45.48 on 4 Nov 2026, up 25.5% over the past year.
From India you can buy VCEL in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Vericel Corporation (VCEL) shares from India?

Do I need the price of a whole VCEL share to invest?

How much can I invest in US stocks in a year?

Can I trade VCEL options or futures?

Insights

Quotes run fifteen minutes behind.

Rose 10.7% on 4 Nov 2026
The 4 Nov 2026 gain of 10.7% was 5.2× its average daily move of 2.0% over the past year, and its largest one-day gain since 9 Apr 2025.
Daily closes, split-adjusted · as of 4 Nov 2026
9.5 days to cover short interest
5.2M shares were sold short at the 15 Oct 2026 settlement, 10.2% of the 51.2M shares outstanding; covering them would take 9.5 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Volume 3.3× its 30-session average on 4 Nov 2026
4 Nov 2026 volume of 1.8M shares was 3.3× the average of the 30 sessions before it (548.1K), as the price rose 10.7%. SPY traded 1.5× its own average that session.
Daily volume against a 30-session baseline · as of 4 Nov 2026
Ahead of SPY, behind its sector fund XLV over 1 year
1 month: +13.6% (SPY −1.6%, XLV +13.5%). 3 months: +0.3% (SPY −0.4%, XLV +15.5%). 1 year: +25.5% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: VCEL, SPY and XLV · as of 4 Nov 2026
Above its 50- and 200-day averages
The 4 Nov 2026 close of $45.48 was 12.1% above its 50-day average ($40.56) and 17.4% above its 200-day average ($38.72). It has closed above the 200-day for 39 sessions, since 11 Sep 2026. The 50-day average crossed above the 200-day on 23 Jun 2026, 94 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month+13.6%

6 months+23.7%

1 year+25.5%

5 years−6.5%

Newswire

About

Website

Notable moves

November 10, 2022
+26.97%
November 9, 2022
−23.43%
February 24, 2022
+20.82%

Vericel Corporation

Vericel Corporation in brief

Rose 10.7% on 4 Nov 2026

9.5 days to cover short interest

Volume 3.3× its 30-session average on 4 Nov 2026

Ahead of SPY, behind its sector fund XLV over 1 year

Above its 50- and 200-day averages

Vericel Corporation

Vericel Corporation in brief

Rose 10.7% on 4 Nov 2026

9.5 days to cover short interest

Volume 3.3× its 30-session average on 4 Nov 2026

Ahead of SPY, behind its sector fund XLV over 1 year

Above its 50- and 200-day averages